EyePoint (EYPT) Raw Materials (2018 - 2026)
EyePoint (EYPT) posted Raw Materials of $1.2 million for Q1 2026, down 5.13% sequentially from $1.2 million in Q4 2025, and down 34.86% YoY from $1.8 million in Q1 2025.
EyePoint (EYPT) Raw Materials (2018 - 2026) Analysis & Trends
EyePoint has reported Raw Materials for 9 years, with the latest figure at $1.2 million in Q1 2026.
- Quarterly Raw Materials fell 34.86% year-over-year to $1.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.2 million (down 34.86% YoY) and the FY2025 annual result came in at $1.2 million, down 25.83% from the prior year.
- Raw Materials declined to $1.2 million in Q1 2026 per EYPT's latest filing, from $1.2 million in the prior quarter.
- Over five years, Raw Materials peaked at $1.9 million in Q2 2022 and troughed at $1.1 million in Q2 2023.
- A 5-year average of $1.5 million and a median of $1.5 million in 2024 frame the typical range for Raw Materials.
- The sharpest annual moves came in 2022 and 2024: Raw Materials slumped 48.29% in 2022, then soared 30.58% in 2024.
- Over 5 years, Raw Materials stood at $1.4 million in 2022, then fell by 7.59% to $1.3 million in 2023, then rose by 27.17% to $1.7 million in 2024, then decreased by 25.83% to $1.2 million in 2025, then decreased by 5.13% to $1.2 million in 2026.
- According to Business Quant data, Raw Materials over the past three periods registered $1.2 million, $1.2 million, and $1.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | EyePoint | 1.25 Bn | 1.07 Bn | 507,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.12 Mn |
| Mar 31, 2026 | 1.17 Mn |
| Dec 31, 2025 | 1.23 Mn |
| Sep 30, 2025 | 1.61 Mn |
| Jun 30, 2025 | 1.68 Mn |
| Mar 31, 2025 | 1.79 Mn |
| Dec 31, 2024 | 1.66 Mn |
| Sep 30, 2024 | 1.50 Mn |
| Jun 30, 2024 | 1.49 Mn |
| Mar 31, 2024 | 1.45 Mn |
| Dec 31, 2023 | 1.30 Mn |
| Sep 30, 2023 | 1.27 Mn |
| Jun 30, 2023 | 1.14 Mn |
| Mar 31, 2023 | 1.27 Mn |
| Dec 31, 2022 | 1.41 Mn |
| Sep 30, 2022 | 1.70 Mn |
| Jun 30, 2022 | 1.95 Mn |
| Mar 31, 2022 | 1.63 Mn |
| Dec 31, 2021 | 2.73 Mn |
| Sep 30, 2021 | 2.79 Mn |